Quick Summary:
In today's rapidly evolving healthcare scene, understanding the future of the global Inhalation and Nasal Spray Generic Drugs market is paramount. This comprehensive market research report is an invaluable tool for senior executives aiming to stay ahead in this fiercely competitive space. It provides an in-depth analysis of the current market size, estimated to be US$29.7 Billion in 2022, and its projected growth to US$45.3 Billion by 2030.
This report provides critical insights on key segments such as corticosteroids projected to record 5.2% CAGR and Bronchodilators readjusted to a revised 5.5% CAGR in this post-pandemic recovery era. It also provides detailed breakdowns of the markets in leading economies, including the U.S. and China. The competitive analysis demonstrates the market position of top players, such as Acerus Pharmaceuticals and Mylan N.V., among others, thereby enabling strategic decision making. To add, the report comes with one year of complimentary updates, ensuring you stay informed with the latest trends and shifts in the industry.
Global Inhalation and Nasal Spray Generic Drugs Market to Reach $45.3 Billion by 2030
The global market for Inhalation and Nasal Spray Generic Drugs estimated at US$29.7 Billion in the year 2022, is projected to reach a revised size of US$45.3 Billion by 2030, growing at a CAGR of 5.4% over the analysis period 2022-2030. Corticosteroids, one of the segments analyzed in the report, is projected to record 5.2% CAGR and reach US$11 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Bronchodilator segment is readjusted to a revised 5.5% CAGR for the next 8-year period.
The U.S. Market is Estimated at $8.9 Billion, While China is Forecast to Grow at 5.2% CAGR
The Inhalation and Nasal Spray Generic Drugs market in the U.S. is estimated at US$8.9 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$8 Billion by the year 2030 trailing a CAGR of 5.2% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5% and 4.6% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 5.2% CAGR.Select Competitors (Total 42 Featured) -
- Acerus Pharmaceuticals
- Akorn
- Allergan PLC
- Apotex
- Astra Zenaca
- Beximco Pharmaceuticals
- Cipla Ltd.
- Hikma (Roxane)
- Mylan N.V.
- Nephron Pharmaceuticals Corporation
- Nippon Shinyaku Co., Ltd.
- Ranbaxy Laboratories Ltd.
- Roxane Laboratories, Inc.
- Sandoz (Novartis AG)
- Sun Pharma (Ranbaxy)
- Teva Pharmaceutical
- XIANJU Pharma
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and the publisher's Research Platform
- Complimentary updates for one year
Frequently Asked Questions about the Global Market for Inhalation and Nasal Spray Generic Drugs
What is the estimated value of the Global Market for Inhalation and Nasal Spray Generic Drugs?
The Global Market for Inhalation and Nasal Spray Generic Drugs was estimated to be valued at $29.7 Billion in 2022.
What is the growth rate of the Global Market for Inhalation and Nasal Spray Generic Drugs?
The growth rate of the Global Market for Inhalation and Nasal Spray Generic Drugs is 5.4%, with an estimated value of $45.3 Billion by 2030.
What is the forecasted size of the Global Market for Inhalation and Nasal Spray Generic Drugs?
The Global Market for Inhalation and Nasal Spray Generic Drugs is estimated to be worth $45.3 Billion by 2030.
Who are the key companies in the Global Market for Inhalation and Nasal Spray Generic Drugs?
Key companies in the Global Market for Inhalation and Nasal Spray Generic Drugs include Acerus Pharmaceuticals, Akorn, Allergan PLC, Apotex, Astra Zenaca, Beximco Pharmaceuticals, Cipla Ltd., Hikma (Roxane), Mylan N.V. and Nephron Pharmaceuticals Corporation.
| Report Attribute | Details |
|---|---|
| No. of Pages | 194 |
| Published | September 2023 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value ( USD | $ 29.7 Billion |
| Forecasted Market Value ( USD | $ 45.3 Billion |
| Compound Annual Growth Rate | 5.4% |
| Regions Covered | Global |
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERSIV. COMPETITION
1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Inhalation and Nasal Spray Generic Drugs - Global Key Competitors Percentage Market Share in 2022 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
- Impact of Covid-19 and a Looming Global Recession
4. GLOBAL MARKET PERSPECTIVE
- Table 1: World Recent Past, Current & Future Analysis for Inhalation and Nasal Spray Generic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 2: World Historic Review for Inhalation and Nasal Spray Generic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 3: World 16-Year Perspective for Inhalation and Nasal Spray Generic Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2023 & 2030
- Table 4: World Recent Past, Current & Future Analysis for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 5: World Historic Review for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 6: World 16-Year Perspective for Corticosteroids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- Table 7: World Recent Past, Current & Future Analysis for Bronchodilator by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 8: World Historic Review for Bronchodilator by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 9: World 16-Year Perspective for Bronchodilator by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- Table 10: World Recent Past, Current & Future Analysis for Antihistamines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 11: World Historic Review for Antihistamines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 12: World 16-Year Perspective for Antihistamines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- Table 13: World Recent Past, Current & Future Analysis for Combinations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 14: World Historic Review for Combinations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 15: World 16-Year Perspective for Combinations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- Table 16: World Recent Past, Current & Future Analysis for Decongestant Sprays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 17: World Historic Review for Decongestant Sprays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 18: World 16-Year Perspective for Decongestant Sprays by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- Table 19: World Recent Past, Current & Future Analysis for Asthma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 20: World Historic Review for Asthma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 21: World 16-Year Perspective for Asthma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- Table 22: World Recent Past, Current & Future Analysis for COPD by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 23: World Historic Review for COPD by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 24: World 16-Year Perspective for COPD by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- Table 25: World Recent Past, Current & Future Analysis for Allergic Rhinitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 26: World Historic Review for Allergic Rhinitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 27: World 16-Year Perspective for Allergic Rhinitis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- Table 28: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 29: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 30: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- Table 31: World Inhalation and Nasal Spray Generic Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
III. MARKET ANALYSIS
- UNITED STATES
- Inhalation and Nasal Spray Generic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
- Table 32: USA Recent Past, Current & Future Analysis for Inhalation and Nasal Spray Generic Drugs by Drug Class - Corticosteroids, Bronchodilator, Antihistamines, Combinations and Decongestant Sprays - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 33: USA Historic Review for Inhalation and Nasal Spray Generic Drugs by Drug Class - Corticosteroids, Bronchodilator, Antihistamines, Combinations and Decongestant Sprays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 34: USA 16-Year Perspective for Inhalation and Nasal Spray Generic Drugs by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Bronchodilator, Antihistamines, Combinations and Decongestant Sprays for the Years 2014, 2023 & 2030
- Table 35: USA Recent Past, Current & Future Analysis for Inhalation and Nasal Spray Generic Drugs by Application - Asthma, COPD, Allergic Rhinitis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 36: USA Historic Review for Inhalation and Nasal Spray Generic Drugs by Application - Asthma, COPD, Allergic Rhinitis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 37: USA 16-Year Perspective for Inhalation and Nasal Spray Generic Drugs by Application - Percentage Breakdown of Value Sales for Asthma, COPD, Allergic Rhinitis and Other Applications for the Years 2014, 2023 & 2030
- CANADA
- Table 38: Canada Recent Past, Current & Future Analysis for Inhalation and Nasal Spray Generic Drugs by Drug Class - Corticosteroids, Bronchodilator, Antihistamines, Combinations and Decongestant Sprays - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 39: Canada Historic Review for Inhalation and Nasal Spray Generic Drugs by Drug Class - Corticosteroids, Bronchodilator, Antihistamines, Combinations and Decongestant Sprays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 40: Canada 16-Year Perspective for Inhalation and Nasal Spray Generic Drugs by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Bronchodilator, Antihistamines, Combinations and Decongestant Sprays for the Years 2014, 2023 & 2030
- Table 41: Canada Recent Past, Current & Future Analysis for Inhalation and Nasal Spray Generic Drugs by Application - Asthma, COPD, Allergic Rhinitis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 42: Canada Historic Review for Inhalation and Nasal Spray Generic Drugs by Application - Asthma, COPD, Allergic Rhinitis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 43: Canada 16-Year Perspective for Inhalation and Nasal Spray Generic Drugs by Application - Percentage Breakdown of Value Sales for Asthma, COPD, Allergic Rhinitis and Other Applications for the Years 2014, 2023 & 2030
- JAPAN
- Inhalation and Nasal Spray Generic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
- Table 44: Japan Recent Past, Current & Future Analysis for Inhalation and Nasal Spray Generic Drugs by Drug Class - Corticosteroids, Bronchodilator, Antihistamines, Combinations and Decongestant Sprays - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 45: Japan Historic Review for Inhalation and Nasal Spray Generic Drugs by Drug Class - Corticosteroids, Bronchodilator, Antihistamines, Combinations and Decongestant Sprays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 46: Japan 16-Year Perspective for Inhalation and Nasal Spray Generic Drugs by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Bronchodilator, Antihistamines, Combinations and Decongestant Sprays for the Years 2014, 2023 & 2030
- Table 47: Japan Recent Past, Current & Future Analysis for Inhalation and Nasal Spray Generic Drugs by Application - Asthma, COPD, Allergic Rhinitis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 48: Japan Historic Review for Inhalation and Nasal Spray Generic Drugs by Application - Asthma, COPD, Allergic Rhinitis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 49: Japan 16-Year Perspective for Inhalation and Nasal Spray Generic Drugs by Application - Percentage Breakdown of Value Sales for Asthma, COPD, Allergic Rhinitis and Other Applications for the Years 2014, 2023 & 2030
- CHINA
- Inhalation and Nasal Spray Generic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
- Table 50: China Recent Past, Current & Future Analysis for Inhalation and Nasal Spray Generic Drugs by Drug Class - Corticosteroids, Bronchodilator, Antihistamines, Combinations and Decongestant Sprays - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 51: China Historic Review for Inhalation and Nasal Spray Generic Drugs by Drug Class - Corticosteroids, Bronchodilator, Antihistamines, Combinations and Decongestant Sprays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 52: China 16-Year Perspective for Inhalation and Nasal Spray Generic Drugs by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Bronchodilator, Antihistamines, Combinations and Decongestant Sprays for the Years 2014, 2023 & 2030
- Table 53: China Recent Past, Current & Future Analysis for Inhalation and Nasal Spray Generic Drugs by Application - Asthma, COPD, Allergic Rhinitis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 54: China Historic Review for Inhalation and Nasal Spray Generic Drugs by Application - Asthma, COPD, Allergic Rhinitis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 55: China 16-Year Perspective for Inhalation and Nasal Spray Generic Drugs by Application - Percentage Breakdown of Value Sales for Asthma, COPD, Allergic Rhinitis and Other Applications for the Years 2014, 2023 & 2030
- EUROPE
- Inhalation and Nasal Spray Generic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
- Table 56: Europe Recent Past, Current & Future Analysis for Inhalation and Nasal Spray Generic Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 57: Europe Historic Review for Inhalation and Nasal Spray Generic Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 58: Europe 16-Year Perspective for Inhalation and Nasal Spray Generic Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2023 & 2030
- Table 59: Europe Recent Past, Current & Future Analysis for Inhalation and Nasal Spray Generic Drugs by Drug Class - Corticosteroids, Bronchodilator, Antihistamines, Combinations and Decongestant Sprays - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 60: Europe Historic Review for Inhalation and Nasal Spray Generic Drugs by Drug Class - Corticosteroids, Bronchodilator, Antihistamines, Combinations and Decongestant Sprays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 61: Europe 16-Year Perspective for Inhalation and Nasal Spray Generic Drugs by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Bronchodilator, Antihistamines, Combinations and Decongestant Sprays for the Years 2014, 2023 & 2030
- Table 62: Europe Recent Past, Current & Future Analysis for Inhalation and Nasal Spray Generic Drugs by Application - Asthma, COPD, Allergic Rhinitis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 63: Europe Historic Review for Inhalation and Nasal Spray Generic Drugs by Application - Asthma, COPD, Allergic Rhinitis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 64: Europe 16-Year Perspective for Inhalation and Nasal Spray Generic Drugs by Application - Percentage Breakdown of Value Sales for Asthma, COPD, Allergic Rhinitis and Other Applications for the Years 2014, 2023 & 2030
- FRANCE
- Inhalation and Nasal Spray Generic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
- Table 65: France Recent Past, Current & Future Analysis for Inhalation and Nasal Spray Generic Drugs by Drug Class - Corticosteroids, Bronchodilator, Antihistamines, Combinations and Decongestant Sprays - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 66: France Historic Review for Inhalation and Nasal Spray Generic Drugs by Drug Class - Corticosteroids, Bronchodilator, Antihistamines, Combinations and Decongestant Sprays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 67: France 16-Year Perspective for Inhalation and Nasal Spray Generic Drugs by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Bronchodilator, Antihistamines, Combinations and Decongestant Sprays for the Years 2014, 2023 & 2030
- Table 68: France Recent Past, Current & Future Analysis for Inhalation and Nasal Spray Generic Drugs by Application - Asthma, COPD, Allergic Rhinitis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 69: France Historic Review for Inhalation and Nasal Spray Generic Drugs by Application - Asthma, COPD, Allergic Rhinitis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 70: France 16-Year Perspective for Inhalation and Nasal Spray Generic Drugs by Application - Percentage Breakdown of Value Sales for Asthma, COPD, Allergic Rhinitis and Other Applications for the Years 2014, 2023 & 2030
- GERMANY
- Inhalation and Nasal Spray Generic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
- Table 71: Germany Recent Past, Current & Future Analysis for Inhalation and Nasal Spray Generic Drugs by Drug Class - Corticosteroids, Bronchodilator, Antihistamines, Combinations and Decongestant Sprays - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 72: Germany Historic Review for Inhalation and Nasal Spray Generic Drugs by Drug Class - Corticosteroids, Bronchodilator, Antihistamines, Combinations and Decongestant Sprays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 73: Germany 16-Year Perspective for Inhalation and Nasal Spray Generic Drugs by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Bronchodilator, Antihistamines, Combinations and Decongestant Sprays for the Years 2014, 2023 & 2030
- Table 74: Germany Recent Past, Current & Future Analysis for Inhalation and Nasal Spray Generic Drugs by Application - Asthma, COPD, Allergic Rhinitis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 75: Germany Historic Review for Inhalation and Nasal Spray Generic Drugs by Application - Asthma, COPD, Allergic Rhinitis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 76: Germany 16-Year Perspective for Inhalation and Nasal Spray Generic Drugs by Application - Percentage Breakdown of Value Sales for Asthma, COPD, Allergic Rhinitis and Other Applications for the Years 2014, 2023 & 2030
- ITALY
- Table 77: Italy Recent Past, Current & Future Analysis for Inhalation and Nasal Spray Generic Drugs by Drug Class - Corticosteroids, Bronchodilator, Antihistamines, Combinations and Decongestant Sprays - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 78: Italy Historic Review for Inhalation and Nasal Spray Generic Drugs by Drug Class - Corticosteroids, Bronchodilator, Antihistamines, Combinations and Decongestant Sprays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 79: Italy 16-Year Perspective for Inhalation and Nasal Spray Generic Drugs by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Bronchodilator, Antihistamines, Combinations and Decongestant Sprays for the Years 2014, 2023 & 2030
- Table 80: Italy Recent Past, Current & Future Analysis for Inhalation and Nasal Spray Generic Drugs by Application - Asthma, COPD, Allergic Rhinitis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 81: Italy Historic Review for Inhalation and Nasal Spray Generic Drugs by Application - Asthma, COPD, Allergic Rhinitis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 82: Italy 16-Year Perspective for Inhalation and Nasal Spray Generic Drugs by Application - Percentage Breakdown of Value Sales for Asthma, COPD, Allergic Rhinitis and Other Applications for the Years 2014, 2023 & 2030
- UNITED KINGDOM
- Inhalation and Nasal Spray Generic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
- Table 83: UK Recent Past, Current & Future Analysis for Inhalation and Nasal Spray Generic Drugs by Drug Class - Corticosteroids, Bronchodilator, Antihistamines, Combinations and Decongestant Sprays - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 84: UK Historic Review for Inhalation and Nasal Spray Generic Drugs by Drug Class - Corticosteroids, Bronchodilator, Antihistamines, Combinations and Decongestant Sprays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 85: UK 16-Year Perspective for Inhalation and Nasal Spray Generic Drugs by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Bronchodilator, Antihistamines, Combinations and Decongestant Sprays for the Years 2014, 2023 & 2030
- Table 86: UK Recent Past, Current & Future Analysis for Inhalation and Nasal Spray Generic Drugs by Application - Asthma, COPD, Allergic Rhinitis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 87: UK Historic Review for Inhalation and Nasal Spray Generic Drugs by Application - Asthma, COPD, Allergic Rhinitis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 88: UK 16-Year Perspective for Inhalation and Nasal Spray Generic Drugs by Application - Percentage Breakdown of Value Sales for Asthma, COPD, Allergic Rhinitis and Other Applications for the Years 2014, 2023 & 2030
- REST OF EUROPE
- Table 89: Rest of Europe Recent Past, Current & Future Analysis for Inhalation and Nasal Spray Generic Drugs by Drug Class - Corticosteroids, Bronchodilator, Antihistamines, Combinations and Decongestant Sprays - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 90: Rest of Europe Historic Review for Inhalation and Nasal Spray Generic Drugs by Drug Class - Corticosteroids, Bronchodilator, Antihistamines, Combinations and Decongestant Sprays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 91: Rest of Europe 16-Year Perspective for Inhalation and Nasal Spray Generic Drugs by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Bronchodilator, Antihistamines, Combinations and Decongestant Sprays for the Years 2014, 2023 & 2030
- Table 92: Rest of Europe Recent Past, Current & Future Analysis for Inhalation and Nasal Spray Generic Drugs by Application - Asthma, COPD, Allergic Rhinitis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 93: Rest of Europe Historic Review for Inhalation and Nasal Spray Generic Drugs by Application - Asthma, COPD, Allergic Rhinitis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 94: Rest of Europe 16-Year Perspective for Inhalation and Nasal Spray Generic Drugs by Application - Percentage Breakdown of Value Sales for Asthma, COPD, Allergic Rhinitis and Other Applications for the Years 2014, 2023 & 2030
- ASIA-PACIFIC
- Inhalation and Nasal Spray Generic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
- Table 95: Asia-Pacific Recent Past, Current & Future Analysis for Inhalation and Nasal Spray Generic Drugs by Drug Class - Corticosteroids, Bronchodilator, Antihistamines, Combinations and Decongestant Sprays - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 96: Asia-Pacific Historic Review for Inhalation and Nasal Spray Generic Drugs by Drug Class - Corticosteroids, Bronchodilator, Antihistamines, Combinations and Decongestant Sprays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 97: Asia-Pacific 16-Year Perspective for Inhalation and Nasal Spray Generic Drugs by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Bronchodilator, Antihistamines, Combinations and Decongestant Sprays for the Years 2014, 2023 & 2030
- Table 98: Asia-Pacific Recent Past, Current & Future Analysis for Inhalation and Nasal Spray Generic Drugs by Application - Asthma, COPD, Allergic Rhinitis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 99: Asia-Pacific Historic Review for Inhalation and Nasal Spray Generic Drugs by Application - Asthma, COPD, Allergic Rhinitis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 100: Asia-Pacific 16-Year Perspective for Inhalation and Nasal Spray Generic Drugs by Application - Percentage Breakdown of Value Sales for Asthma, COPD, Allergic Rhinitis and Other Applications for the Years 2014, 2023 & 2030
- REST OF WORLD
- Table 101: Rest of World Recent Past, Current & Future Analysis for Inhalation and Nasal Spray Generic Drugs by Drug Class - Corticosteroids, Bronchodilator, Antihistamines, Combinations and Decongestant Sprays - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 102: Rest of World Historic Review for Inhalation and Nasal Spray Generic Drugs by Drug Class - Corticosteroids, Bronchodilator, Antihistamines, Combinations and Decongestant Sprays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 103: Rest of World 16-Year Perspective for Inhalation and Nasal Spray Generic Drugs by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Bronchodilator, Antihistamines, Combinations and Decongestant Sprays for the Years 2014, 2023 & 2030
- Table 104: Rest of World Recent Past, Current & Future Analysis for Inhalation and Nasal Spray Generic Drugs by Application - Asthma, COPD, Allergic Rhinitis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 105: Rest of World Historic Review for Inhalation and Nasal Spray Generic Drugs by Application - Asthma, COPD, Allergic Rhinitis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 106: Rest of World 16-Year Perspective for Inhalation and Nasal Spray Generic Drugs by Application - Percentage Breakdown of Value Sales for Asthma, COPD, Allergic Rhinitis and Other Applications for the Years 2014, 2023 & 2030
Companies Mentioned
A selection of companies mentioned in this report includes:
- Acerus Pharmaceuticals
- Akorn
- Allergan PLC
- Apotex
- Astra Zenaca
- Beximco Pharmaceuticals
- Cipla Ltd.
- Hikma (Roxane)
- Mylan N.V.
- Nephron Pharmaceuticals Corporation
- Nippon Shinyaku Co., Ltd.
- Ranbaxy Laboratories Ltd.
- Roxane Laboratories, Inc.
- Sandoz (Novartis AG)
- Sun Pharma (Ranbaxy)
- Teva Pharmaceutical
- XIANJU Pharma
